Open AccessEffects of Chronic Rosiglitazone Treatment on Renal Handling of Salt and Water in Rats With Volume-Overload Congestive Heart Failure
Author(s) -
Ilia Goltsman,
Xinkang Wang,
Edward R. LaVallie,
Elizabeth A. DiBlasio-Smith,
Elena Ovcharenko,
Aaron Hoffman,
Zaid Abassi,
Giora Feuerstein,
Joseph Winaver
Publication year - 2011
Publication title -
circulation heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 104
eISSN - 1941-3297
pISSN - 1941-3289
DOI - 10.1161/circheartfailure.110.960179
Subject(s) - rosiglitazone , medicine , pioglitazone , heart failure , saline , endocrinology , thiazolidinedione , volume overload , diuretic , excretion , diabetes mellitus , receptor , type 2 diabetes
The side effects of fluid retention and edema of the thiazolidinedione (TZD) class of peroxisome proliferator-activated receptor-γ agonists limit their use in patients with congestive heart failure (CHF). The present study aims to explore whether chronic treatment with the TZD compound rosiglitazone (RGZ) is associated with worsening of salt and water retention in male Sprague-Dawley rats with aorto-caval fistula, an experimental model of volume-overload CHF.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom